THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS

被引：0
|
作者：
Suboticki, T. [1 ]
Cokic, B. Beleslin [2 ]
Djikic, D. [1 ]
Mojsilovic, S. [3 ]
Sefer, D. [4 ]
Bjelica, S. [3 ]
Santibanez, J. [3 ]
Cokic, V. [3 ]
机构：
[1] Univ Belgrade, Inst Med Res, Lab Neuroendocrinol, Belgrade, Serbia
[2] Clin Ctr Serbia, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia
[3] Univ Belgrade, Inst Med Res, Lab Expt Hematol, Belgrade, Serbia
[4] Clin Ctr Serbia, Clin Hematol, Belgrade, Serbia
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1308
引用
收藏
页码：536 / 537
页数：2
相关论文
共 50 条
  • [31] Pharmaceutical intervention in the JAK/STAT signaling pathway
    Seidel, HM
    Lamb, P
    Rosen, J
    ONCOGENE, 2000, 19 (21) : 2645 - 2656
  • [32] Arsenic inhibition of the JAK-STAT pathway
    Haiyun Y Cheng
    Ping Li
    Michael David
    Thomas E Smithgall
    Lili Feng
    Michael W Lieberman
    Oncogene, 2004, 23 : 3603 - 3612
  • [33] Arsenic inhibition of the JAK-STAT pathway
    Cheng, HYY
    Li, P
    David, M
    Smithgall, TE
    Feng, LL
    Lieberman, MW
    ONCOGENE, 2004, 23 (20) : 3603 - 3612
  • [34] ERK and MEK kinases as novel therapeutic targets in myeloproliferative neoplasms based on bypass MAPK pathway activation
    Stivala, S.
    Baerenwaldt, A.
    Codilupi, T.
    Ghosh, N.
    Hao-Shen, H.
    Dirnhofer, S.
    Dettmer, M. S.
    Simillion, C.
    Chiu, S.
    Keller, M.
    Kleppe, M.
    Hilpert, M.
    Buser, A.
    Passweg, J. R.
    Radimerski, T.
    Skoda, R. C.
    Levine, R. L.
    Meyer, S. C.
    SWISS MEDICAL WEEKLY, 2018, 148 : 28S - 28S
  • [35] JAK2 Signaling Specifies Phenotypic Pleiotropy In Myeloproliferative Neoplasms
    Huang, Lily
    Yao, Huiyu
    Ma, Yue
    BLOOD, 2013, 122 (21)
  • [36] Targeting JAK2 pathway mutations for treatment of myeloproliferative neoplasms
    Purandare, Ashok V.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [37] JAK-STAT pathway activation in COPD
    Yew-Booth, Liang
    Birrell, Mark A.
    Lau, Ming Sum
    Baker, Katie
    Jones, Victoria
    Kilty, Iain
    Belvisi, Maria G.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (03) : 843 - 845
  • [38] Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-κB Signaling to Pathogenesis of Myeloproliferative Neoplasms
    Chorzalska, Anna Dorota
    Morgan, John
    Treaba, Diana Olguta
    Olszewski, Adam J.
    Lombardo, Kara
    Zini, Roberta
    Pacilli, Annalisa
    Tepper, Alexander
    Reagan, John L.
    Kotula, Leszek
    Quesenberry, Peter J.
    Gruppuso, Philip
    Manfredini, Rossella
    Vannucchi, Alessandro M.
    Dubielecka, Patrycja
    BLOOD, 2017, 130
  • [39] Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms
    Barrio, Santiago
    Gallardo, Miguel
    Arenas, Alicia
    Ayala, Rosa M.
    Rapado, Inmaculada
    Rueda, Daniel
    Jimenez, Ana
    Albizua, Enriqueta
    Burgaleta, Carmen
    Gilsanz, Florinda
    Martinez, Joaquin
    BLOOD, 2012, 120 (21)
  • [40] JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside
    Gotlib, Jason
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 529 - 537
12345